By Fineline Cube 
China-based Grand Pharmaceutical Group Limited (HKG: 0512) announced that its innovative radiolabeled drug conjugate (RDC) TLX591 has received approval from the National Medical Products Administration (NMPA) to join a Phase III international multicenter clinical trial for prostate cancer treatment.
TLX591: Targeted Therapy for Prostate Cancer
TLX591 is designed to target prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC). The drug requires only a two-dose regimen administered 14 days apart, significantly reducing treatment duration and improving patient compliance. This innovative approach highlights Grand Pharmaceutical’s commitment to advancing targeted therapies for prostate cancer.
Strategic Partnership with Telix Pharmaceuticals
In November 2020, Grand Pharmaceutical Group entered into a strategic cooperation agreement with Telix Pharmaceutical Limited (ASX: TLX, NASDAQ: TLX). The agreement granted Grand Pharma exclusive rights in Greater China (including Mainland China, Hong Kong, Macao, and Taiwan) for multiple innovative RDC products developed by Telix, including TLX591, TLX591-CDx, and TLX250-CDx. This partnership underscores Grand Pharma’s dedication to bringing cutting-edge radiopharmaceuticals to Chinese patients.-Fineline Info & Tech